A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer

Launched by THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY · Mar 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how effective and safe a combination of a medication called abemaciclib with standard hormone therapy is for women with hormone receptor-positive (HR+) breast cancer. The study aims to gather information about how well this treatment works in real-life situations, any side effects that may occur, and the overall costs involved in the treatment process.

To participate, women must be at least 18 years old and have been diagnosed with HR+ breast cancer that has spread to other parts of the body. They also need to have received treatment with abemaciclib along with any form of hormone therapy. However, women who have other serious health issues, are pregnant or breastfeeding, or have male breast cancer cannot participate. The trial is not yet recruiting participants, so there will be more information to come on how to get involved. If eligible, participants can expect to share their experiences and medical records, which will help researchers understand the treatment's impact better.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • Histologically confirmed HR-positive breast cancer and Imaging/pathological evidence of metastasis is available
• • Treatment with abemaciclib in combination with endocrine therapy
• • Any endocrine therapy
• • Having solid tumor efficacy evaluation criteria RECIST 1.1 measurable lesions
• Exclusion Criteria:
• • Combined with other primary malignancies
• • Associated with serious non-tumor related diseases, such as cardiovascular system, respiratory system, nervous system, blood system, digestive system
• • Pregnant or lactating women
• • male breast cancer